Jun 22, 2020
Lung Cancer Research Foundation Names Dr. Trudy Oliver to its Scientific Advisory Board
Jun 15, 2020
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca(TM) (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
Jun 03, 2020
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
May 29, 2020
Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
May 19, 2020
Small Cell Lung Cancer (SCLC) Market Insights, Epidemiology and Forecast to 2030
May 13, 2020
TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 12, 2020
Non-Small Cell Lung Cancer (NSCLC) Market Forecasts to 2030: A Comprehensive Insight
May 11, 2020
Bionical Emas and Jazz Pharmaceuticals Enter into an Agreement for Expanded Access to Lurbinectedin in Relapsed Small Cell Lung Cancer in the United States
May 05, 2020
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
Apr 27, 2020
Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting
Mar 24, 2020
Non-Small Cell Lung Cancer Treatment Market to Surpass US$ 39,395.2 Million, Globally, by the end of 2027 - CMI
Mar 17, 2020
4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate
Mar 16, 2020
2020 Market Spotlight: Small-Cell Lung Cancer (SCLC)
Feb 27, 2020
Global Lung Cancer Therapeutics Market: Growth, Trends & Forecasts (2020-2025)
Feb 25, 2020
IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer
Feb 20, 2020
Small Cell Lung Cancer Market Size is Expected to Increase at a CAGR of 13.2% for the Study Period (2017-2030) in the 7MM | Some Market Key Players - AstraZeneca, PharmaMar, EpicentRx, United Therapeutics, Ipsen, G1 Therapeutics, Otsuka Holdings, Takeda
Feb 17, 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Jan 27, 2020
PharmaMar and Bionical Emas Launch Expanded Access Program for Lurbinectedin in Relapsed Small Cell Lung Cancer in the U.S.
Jan 16, 2020
Educational Lung Cancer Event Coming to Houston to Raise Awareness of State's High Rate of Lung Cancer
Jan 13, 2020
Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC